Shots:
- Caribou to receive $40M up front in cash & equity investment, ~$300M in development, regulatory, and launch milestones along with additional commercial milestones and global royalties
- AbbVie will utilize and gets exclusive rights to Caribou’s next-generation Cas12a chRDNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies directed to specified targets
- Caribou will responsible for pre-clinical research, development, and manufacturing activities for the collaboration programs and AbbVie will reimburse Caribou for all such activities pursuant to the deal
Click here to read full press release/ article | Ref: Abbvie | Image: WSJ
The post AbbVie Signs a License Agreement with Caribou Biosciences for CAR-T Cell Therapies first appeared on PharmaShots.
